NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025
key details
| Value | £4,108,145,000 |
|---|---|
| Status | complete |
| Category (CPV) | 33600000 |
| Deadline | 7 Apr 2025 |
| Contract start | 1 Sept 2025 |
| Contract end | 31 Aug 2027 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-04aa1520-7ead-4f1f-bebb-422062580323 |
Awards (21)
This procurement was awarded to 21 suppliers. Values shown are per-award; the notice total is £4,108,145,000.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Abbvie Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Accord-UK Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Alexion Pharmaceuticals shared | £986,282,758 | 30 Jun 2025 | active |
| Amgen Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Biogen shared | £986,282,758 | 30 Jun 2025 | active |
| Celltrion Healthcare United Kingdom Limited shared | £986,282,758 | 30 Jun 2025 | active |
| CuraTeQ Biologics s.r.o. shared | £986,282,758 | 30 Jun 2025 | active |
| Dr.Reddy's Laboratories (UK) Limited shared | £986,282,758 | 30 Jun 2025 | active |
| Fresenius Kabi Limited shared | £986,282,758 | 30 Jun 2025 | active |
| GlaxoSmithKline UK Limited shared | £986,282,758 | 30 Jun 2025 | active |
| Janssen-Cilag Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Organon Pharmaceuticals UK Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Orifarm UK shared | £986,282,758 | 30 Jun 2025 | active |
| Pfizer Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Roche Products Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Samsung Bioepis UK Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Sandoz Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Sobi (Swedish Orphan Biovitrum Ltd) shared | £986,282,758 | 30 Jun 2025 | active |
| Takeda UK Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Thornton and Ross Ltd shared | £986,282,758 | 30 Jun 2025 | active |
| Zentiva Pharma UK Ltd shared | £986,282,758 | 30 Jun 2025 | active |
description
NHS Framework Agreement for Branded Medicines - Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025
CM/PHR/24/5680/01 - NHS Framework Agreement for Branded Medicines - Tranche B for North of England and Midlands & East. Period of Framework Agreement: 01 September 2025 to 31 August 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CM/PHR/24/5680/02 - NHS Framework Agreement for Branded Medicines - Eculizumab and Ravulizumab for London & SOFE. Period of Framework Agreement: 01 September 2025 to 31 August 2026 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 29 Jul 2025 | Award (award) | · | cc644418-f584-45db-bf35-771baf03bc48-856590 |
more from NHS England
- Urgent Award - haematological screening · £16,202 · 29 Jul 2026
- HSCN-AWS Connectivity Service for Spine · £228,060 · 29 Jul 2026
- Incentive Voucher Provider · £60,000 · 29 Jul 2026
- CRM for NHSE participant/candidate data 26-27 · £56,640 · 28 Jul 2026
- Wayfinder and First Contact Digital Clinical Support 2026-27 · £748,000 · 23 Jul 2026
- Support Services for PPM application · £860,000 · 22 Jul 2026
- Digital Maturity Assessment · 21 Jul 2026
- Integrated Healthcare Services to Haslar Immigration Removal Centre (IRC) · £19,052,186 · 13 Jul 2026
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.